Swiss life science and biotech company Arcoris Bio completed a CHF 6.3m seed financing round. In connection with the operation, Wenger Vieli advised Arcoris Bio, while MLL Legal represented German biotech investment fund Ventura Ace
Globally active biopharmaceutical company AstraZeneca has exercised an option to acquire obesity drug startup SixPeaks Bio. In connection with the deal, Lenz & Staehelin represented AstraZeneca, while Walder Wyss advised SixPeaks Bio and its shareholders.
Baker McKenzie advised Fundamenta Real Estate (Fundamenta) on its rights offering, which closed today with proceeds of CHF 70 million. The operation – backed by firm commitments in the amount of CHF 41.9 million – resulted in the issuance
Welcome to our weekly newsletter, check out the highlights from legalcommunity.ch’s newsroom. · Kellerhals Carrard advised Lakera – a AI Swiss startup founded by entrepreneurs David Haber, Matthias Kraft, and Mateo Rojas-Carulla – as well as
Swiss-based Mageba Group completed a refinancing operation via a syndicated loan with a banking consortium led by UBS Switzerland. In connection with the deal, Niederer Kraft Frey (NKF) advised UBS Switzerland, as well as the
Niederer Kraft Frey advised CoinShares, a digital asset investment firm with over USD 9.5 billion in AUM, on the listing of its physically-backed Toncoin exchange-traded product (ETP) on the SIX Swiss Exchange in Zurich. The company
Bratschi represented the University Hospital Basel in the merger proceedings before the COMCO, as the commission examined the hospital’s takeover of the Claraspital Basel and the other companies in the Clara Group, and decided
Wenger Vieli advised DeepJudge, a Zurich-based specialist in legal AI platforms, throughout its USD 41.2 million series A financing round. Silicon Valley venture capital firm Felicis led the round in question, with further support from existing
Bär & Karrer advised Oxford University Press, as the publishing house of the University of Oxford signed an agreement to acquire 100 percent of the shares in S. Karger, a Basel-based specialist publisher focusing on
Vischer advises Oculis Holding, as the globally active biopharmaceutical company announced the pricing of offerings for an aggregate of 5,432,098 of its ordinary shares. The stocks value at $20.25 per unit, for total gross proceeds of USD 110
